Magazine Article | March 1, 2017

Pharmaceuticals Escape The Knife As GOP Mulls Medicaid Reform

By John McManus, president and founder, The McManus Group

After bracing for the worst, pharmaceutical executives emerged from a White House meeting with newly installed President Donald J. Trump relatively unscathed. But they soon concluded that his ever-roving spotlight would be back on them in a matter of time and it was on them to develop proposals that would reduce the cost of drugs when patients show up at a pharmacy.

Eli Lilly CEO David Ricks later commented that the discussion focused on consumer out-of-pocket costs, and drug companies need to do a better job “getting discounts through to consumers.”

THIS CONTENT IS EXCLUSIVELY FOR LIFE SCIENCE LEADER PAID SUBSCRIBERS.
To continue reading this story and receive uninterrupted access to LSL Online and its monthly magazine subscribe to Life Science Leader today!
Already a subscriber? Log in now.